Connect your AI

BridgeBio Pharma BBIO Proceeds From Payments To Minority Shareholders

Proceeds From Payments To Minority Shareholders at other companies

LennarLEN

-$6.62M+69.7%

Willis Towers WatsonWTW

-$32M-700%

Expedia Group, Inc.EXPE

$52M+2,542%

NRG EnergyNRG

$0—

Air Products and ChemicalsAPD

$1.8M-72.1%

Regency CentersREG

$0—

Other financials

Income statement

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsToMinorityShareholders.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's proceeds from payments to minority shareholders.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BridgeBio Pharma's proceeds from payments to minority shareholders?: BridgeBio Pharma (BBIO) reported proceeds from payments to minority shareholders of $0 in Q1 2026.
How has BridgeBio Pharma's proceeds from payments to minority shareholders changed year-over-year?: BridgeBio Pharma's proceeds from payments to minority shareholders decreased by 100.0% year-over-year, from $800K to $0.